Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer

Hum Vaccin Immunother. 2022 Nov 30;18(5):2060019. doi: 10.1080/21645515.2022.2060019. Epub 2022 Apr 25.

Abstract

Cervical cancer is one of the most common malignancies among females. As a virus-related cancer, cervical cancer has attracted a lot of attention to develop virus-targeted immune therapy, including vaccine and adoptive immune cell therapy (ACT). Adoptive tumor infiltrating lymphocytes (TILs) cell therapy has been found to be able to control advanced disease progression in some cervical cancer patients who have received several lines of treatment in a pilot clinical trial. In addition, sustainable therapeutic effect has been identified in some cases. The safety risks of TIL therapy for patients are minimal or at least manageable. In this review, we focused on the versatility of TILs and tried to summarize potential strategies to improve the therapeutic effect of TILs and discuss related perspectives.

Keywords: Cervical cancer; adoptive tumor infiltrating lymphocytes; immune therapy; potential strategies for improvement.

Publication types

  • Review

MeSH terms

  • Cell- and Tissue-Based Therapy
  • Female
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Lymphocytes, Tumor-Infiltrating*
  • Uterine Cervical Neoplasms* / pathology
  • Uterine Cervical Neoplasms* / therapy

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.